表紙
市場調査レポート

脳性麻痺:パイプライン分析

Cerebral Palsy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200937
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
脳性麻痺:パイプライン分析 Cerebral Palsy - Pipeline Review, H2 2016
出版日: 2016年07月13日 ページ情報: 英文 46 Pages
概要

脳性麻痺は、運動、学習、視聴覚、思考など脳や神経系の機能に関連する一群の障害であり、筋緊張、異常歩行、腕、膝の拘縮、つま先での歩行、構音障害、視聴覚の障害疼痛などの症状があります。治療法には、抗けいれん薬や筋弛緩薬の利用などがあります。

当レポートでは、世界における脳性麻痺治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

脳性麻痺の概要

治療薬の開発

  • 脳性麻痺向けパイプライン製品:概要
  • 脳性麻痺向けパイプライン製品:比較分析

脳性麻痺:開発中の治療薬:企業別

脳性麻痺:開発中の治療薬:大学・研究機関別

脳性麻痺:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

脳性麻痺:開発中の製品:企業別

脳性麻痺:開発中の製品:大学・研究機関別

脳性麻痺:治療薬開発に従事している企業

  • Allergan Plc
  • Cell Cure Neurosciences, Ltd.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.
  • Neuralstem, Inc.

脳性麻痺:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • NeurArrest
  • NSI-566
  • onabotulinumtoxin A
  • 脳性麻痺向け幹細胞治療
  • 脳性麻痺・全身性エリテマトーデス向け幹細胞治療
    • 製品概要
    • 作用機序
    • R&Dの進捗

脳性麻痺:最近のパイプライン動向

脳性麻痺:休止中のプロジェクト

脳性麻痺:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8222IDB

Summary

Global Markets Direct's, 'Cerebral Palsy - Pipeline Review, H2 2016', provides an overview of the Cerebral Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy
  • The report reviews pipeline therapeutics for Cerebral Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cerebral Palsy therapeutics and enlists all their major and minor projects
  • The report assesses Cerebral Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cerebral Palsy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cerebral Palsy Overview
  • Therapeutics Development
    • Pipeline Products for Cerebral Palsy - Overview
  • Cerebral Palsy - Therapeutics under Development by Companies
  • Cerebral Palsy - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cerebral Palsy - Products under Development by Companies
  • Cerebral Palsy - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Cell Cure Neurosciences, Ltd.
    • Cellular Biomedicine Group, Inc.
    • CHA Bio & Diostech Co., Ltd.
    • CytoDel, LLC
    • Neuralstem, Inc.
  • Cerebral Palsy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Cyto-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NeurArrest - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Palsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cerebral Palsy - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cerebral Palsy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Cerebral Palsy - Pipeline by Allergan Plc, H2 2016
  • Cerebral Palsy - Pipeline by Cell Cure Neurosciences, Ltd., H2 2016
  • Cerebral Palsy - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Cerebral Palsy - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016
  • Cerebral Palsy - Pipeline by CytoDel, LLC, H2 2016
  • Cerebral Palsy - Pipeline by Neuralstem, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cerebral Palsy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Cerebral Palsy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top